Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Operator-Assisted Oscilla Audiometry as a Basis for Hearing Aid Fitting (The Oscilla Validation Study)

15. november 2026 oppdatert av: Lene Dahl Siggaard, Aalborg University Hospital

Validation of Operator-Assisted Oscilla Audiometry as a Diagnostic Tool and Basis for Hearing Aid Fitting in Adults With Uncomplicated Hearing Loss: A Blinded Non-Inferiority Randomised Controlled Trial

The purpose of this study is to find out whether hearing tests performed with the Oscilla A60 audiometer, where the patient largely tests themselves with minimal staff assistance, are accurate enough to be used for diagnosing hearing loss and as the sole basis for fitting hearing aids. Adults referred for their first hearing aids at Aalborg University Hospital will have their hearing tested both with the Oscilla audiometer and by a trained audiology assistant at the same visit. Participants are then randomly assigned to receive hearing aids fitted based on either the Oscilla hearing test or the audiology assistant's hearing test. The main questions are: (1) Do the Oscilla results agree with the audiology assistant's results for both air-conduction and bone-conduction hearing thresholds? (2) Do participants fitted based on the Oscilla test report a hearing benefit that is not worse than that of participants fitted based on the standard test, two months after fitting?

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Demand for audiometric testing in public hearing clinics is increasing due to population ageing. Operator-assisted automated audiometry may expand capacity, but its use as the sole basis for hearing aid prescription, and its accuracy for bone-conduction (BC) thresholds, has not been established. This single-site study at the Department of Audiology, Aalborg University Hospital (locations in Aalborg and Hobro) enrols 268 first-time hearing aid users with uncomplicated, symmetric sensorineural hearing loss.

At Visit 1, all participants undergo both Oscilla A60 audiometry (air conduction [AC] 250-8000 Hz; BC 250-4000 Hz) and standard manual audiometry by an audiology assistant (reference standard), in randomised order. Agreement between methods is assessed with Bland-Altman analysis against pre-specified acceptance criteria (95% CI of bias within ±5 dB; 95% limits of agreement within ±15 dB for AC and ±20 dB for BC). After confirmation of eligibility, participants are randomised 1:1, stratified by hearing loss severity (PTA-4 ≤45 vs >45 dB HL) and location, to hearing aid fitting based on the Oscilla audiogram or the audiology assistant audiogram. All participants are fitted bilaterally with BTE/RIC hearing aids to the NAL-NL2 target, verified with automated real-ear measurements (within ±5 dB). Volume control and app connectivity are disabled until the two-month follow-up. The primary patient-reported outcome is the change in SSQ12 total score from baseline to two months post-fitting, with a non-inferiority margin of -0.81 points. Secondary outcomes are IOI-HA, daily hearing aid use (data logging) and SSQ12 subscales. The study is a clinical investigation under Article 82 of Regulation (EU) 2017/745.

Studietype

Intervensjonell

Registrering (Antatt)

268

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Lene D Siggaard, MD, PhD
  • Telefonnummer: +45 20633492
  • E-post: lene.dahl@rn.dk

Studer Kontakt Backup

Studiesteder

      • Aalborg, Danmark, 9000
        • Department of Audiology, Aalborg University Hospital
        • Ta kontakt med:
        • Ta kontakt med:
          • Lene D Siggaard, MD, PhD
          • Telefonnummer: +4520633492
          • E-post: lene.dahl@rn.dk
      • Hobro, Danmark, 9500
        • Hearing Clinic, Aalborg University Hospital
        • Ta kontakt med:
        • Ta kontakt med:
          • Lene D Siggaard, MD, PhD
          • Telefonnummer: +4520633492
          • E-post: lene.dahl@rn.dk

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Adults (≥18 years) referred for first-time hearing aid fitting at the Department of Audiology, Aalborg University Hospital
  • Uncomplicated sensorineural hearing loss as defined by the Danish national clinical guidelines
  • Hearing thresholds exceeding 20 dB HL at two or more frequencies in the range 0.5-4 kHz
  • Pure-tone average (PTA-4; 0.5, 1, 2, 4 kHz) ≥30 dB HL in the better ear
  • Symmetric hearing loss (PTA-4 difference between ears ≤15 dB)
  • Word discrimination score ≥25% (DANTALE I at PTA + 40 dB HL)
  • Danish native speaker
  • No prior hearing aid experience
  • Able to complete questionnaires online or on paper
  • Written informed consent

Exclusion Criteria:

  • Air-conduction thresholds exceeding 80 dB HL at two or more frequencies
  • Air-bone gap >15 dB at one or more frequencies below 1 kHz
  • Fluctuating hearing loss (e.g., Ménière's disease) or ongoing ototoxic medication
  • Ear surgery (ear canal, middle ear or inner ear) within the past 12 months
  • Hearing loss classified as complicated according to national clinical guidelines
  • Visual or motor impairment precluding independent use of the Oscilla system
  • Candidates for in-the-ear hearing aids only (all participants are fitted with BTE or RIC hearing aids)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Diagnostisk
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Oscilla-based fitting

Hearing aids fitted bilaterally to NAL-NL2 targets based on the Oscilla A60 audiogram, verified with automated real-ear measurement. Volume control and app connectivity disabled for two months (linked interventions: Paired audiometry and Oscilla-based hearing aid fitting).

At Visit 1, all participants undergo both operator-assisted Oscilla A60 audiometry (AudioConsole v4.6.0; AC and BC thresholds; operator places the BC headband only) in a quiet room (<50 dB SPL) and manual pure-tone audiometry (AC and BC, ISO 8253-1) by a qualified audiology assistant in a sound-attenuating booth, in randomised order.

Bilateral BTE/RIC hearing aid fitting to NAL-NL2 targets using the Oscilla A60 audiogram as the sole audiometric basis, verified with auto-REM (within ±5 dB of target). Other names: Oscilla A60 Diagnostic Audiometer.

Aktiv komparator: Manual audiometry-based fitting

Hearing aids fitted bilaterally to NAL-NL2 targets based on the audiogram obtained by a qualified audiology assistant, verified with automated real-ear measurement. Volume control and app connectivity disabled for two months (linked interventions: paired audiometry and manual audiometry-based hearing aid fitting).

At Visit 1, all participants undergo both operator-assisted Oscilla A60 audiometry (AudioConsole v4.6.0; AC and BC thresholds; operator places the BC headband only) in a quiet room (<50 dB SPL) and manual pure-tone audiometry (AC and BC, ISO 8253-1) by a qualified audiology assistant in a sound-attenuating booth, in randomised order.

Bilateral BTE/RIC hearing aid fitting to NAL-NL2 targets using the audiology assistant audiogram, verified with auto-REM (within ±5 dB of target). Standard clinical practice.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Agreement between Oscilla A60 and manual audiometry for air-conduction thresholds
Tidsramme: Visit 1 (Week 0)

Bland-Altman mean difference (Oscilla minus manual) and 95% limits of agreement in dB, plus mean absolute difference, at 0.5, 1, 2 and 4 kHz separately. Agreement is acceptable if the 95% CI of the bias is within ±5 dB and the 95% limits of agreement are within ±15 dB. Both ears included, clustering handled with a mixed-effects model.

Visit 1 (Week 0)
Agreement between Oscilla A60 and manual audiometry for bone-conduction thresholds
Tidsramme: Visit 1 (Week 0)

As above for bone-conduction thresholds at 0.5, 1, 2 and 4 kHz. Agreement is acceptable if the 95% CI of the bias is within ±5 dB and the 95% limits of agreement are within ±20 dB.

Visit 1 (Week 0)
Change in SSQ12 total score
Tidsramme: Baseline (Week 0) and 2 months after hearing aid fitting

Speech, Spatial and Qualities of Hearing Scale, 12-item version; total score = mean of 12 items, range 0-10, higher = better. Non-inferiority if the lower bound of the two-sided 95% CI for the between-group difference in change (Oscilla minus control) is above -0.81 points.

Baseline (Week 0) and 2 months after hearing aid fitting

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
IOI-HA total score
Tidsramme: 2 months after hearing aid fitting

International Outcome Inventory for Hearing Aids, Danish version; 7 items scored 1-5, total range 7-35, higher = better outcome. Compared between groups

2 months after hearing aid fitting
Daily hearing aid use
Tidsramme: From hearing aid fitting to 2 months after fitting

Mean daily hearing aid usage time in hours/day from the hearing aid data log, compared between groups

From hearing aid fitting to 2 months after fitting
Change in SSQ12 subscale scores
Tidsramme: Baseline (Week 0) and 2 months after hearing aid fitting

Change in the speech, spatial and qualities subscale scores (each range 0-10, higher = better)

Baseline (Week 0) and 2 months after hearing aid fitting

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Lene D Siggaard, MD, PhD, Department of Otolaryngology, Head- and Neck Surgery and Audiology, Aalborg University Hospital

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

31. oktober 2027

Studiet fullført (Antatt)

31. oktober 2027

Datoer for studieregistrering

Først innsendt

15. november 2026

Først innsendt som oppfylte QC-kriteriene

15. november 2026

Først lagt ut (Faktiske)

19. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • F2026-115
  • Regional Innovation Fund (Annet stipend/finansieringsnummer: North Denmark Region)
  • Danish Medicines Agency (Registeridentifikator: 16-0302-225)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

IPD-planbeskrivelse

Pseudonymised individual participant data may be shared upon reasonable request after publication, subject to approval under the GDPR and Danish data protection law and a data processing agreement.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .